Last reviewed · How we verify

NCT04996849

Contemporary Characteristics of Penile Cancer

Terminated Last updated 24 September 2025
What this trial tests

trial testing Data Capture in Penile Carcinoma in 499 participants. Terminated before completion.

Timeline
22 April 2004
Primary endpoint
17 September 2025
17 September 2025

Quick facts

Lead sponsorM.D. Anderson Cancer Center
StatusTerminated
Study typeOBSERVATIONAL
Enrollment499
Start date22 April 2004
Primary completion17 September 2025
Estimated completion17 September 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, male only, with Penile Carcinoma or Squamous Cell Carcinoma of the Penis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study develops a prospective database of patients who are evaluated and treated for penile cancer. This will facilitate analyzing trends in cancer incidence, risk factors, treatment, complications, and tumor progression. It will also prospectively validate the importance of pathological prognostic factors previously reported and outcome related to contemporary treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Data Capture

Trials testing the same drug.

Other recruiting trials for Penile Carcinoma

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04996849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing